Prescription for Success: Commercialization Efforts, Acquisitions and Enhanced Patent Protection - Research Report on PAREXEL International, Ironwood Pharmaceuticals, Opko Health, Amarin Corporation, Progenics Pharmaceuticals

NEW YORK, March 19, 2013 /PRNewswire/ --

Today, Wall Street Source announced new research reports highlighting PAREXEL International Corporation (NASDAQ: PRXL), Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD), Opko Health Inc. (NYSE: OPK), Amarin Corporation plc (ADR) (NASDAQ: AMRN) and Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

PAREXEL International Corporation Research Report

In the coming year, PAREXEL International hopes to benefit from its acquisition of Liquent Inc., a provider of Regulatory Information Management solutions. This is expected to strengthen the company's technology and regulatory capabilities. The company notes that its healthy backlog of new projects and strong flow of proposals will fuel revenue growth. Furthermore, the company recently provided an update of its share repurchase program, saying that the company expects to receive approximately 265,000 additional shares of the company's common stock upon maturity of the accelerated share repurchase program on March 26, 2013. So far, the company has paid $100 million under its repurchase programs. It also plans to repurchase an additional $50 million worth of shares of its common stock. These are all parts of the company's plans to achieve profitable growth and increase shareholder value. The Full Research Report on PAREXEL International Corporation - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wallstsource.com/r/full_research_report/037f_PRXL]

Ironwood Pharmaceuticals, Inc. Research Report

Ironwood Pharmaceuticals has been impressing analysts due to Linzess sales. The company's shares surged 6 percent after Credit Suisse analyst Catherine Arnold upgraded the company from Neutral to Outperform and significantly raised its price target from $15 to $24. The analyst notes that a survey from her firm of roughly 100 physicians suggest great demand for Linzess, a treatment for irritable bowel syndrome. She also notes that feedback from Linzess users is generally positive and physicians plan to increase prescribing the product in the future. The Bank of America also raised its price target noting the increased number of prescriptions in February. In the future, the company will continue to focus on the successful commercialization of Linzess while also exploring development opportunities to broaden the product in other indications and geographies. The drug will be launched as CONSTELLA in Europe during the first half of 2013. The Full Research Report on Ironwood Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wallstsource.com/r/full_research_report/d5cb_IRWD]

Opko Health Inc. Research Report

Opko Health recently announced a strategic pooling of its assets in the field of RNA interface (RNAi). In the terms of the agreement, RXi Pharmaceuticals Corporation will acquire all of Opko's RNAi-related assets, including its patent portfolio. As payment, RXi will issue to Opko 50 million shares of its common stock and will make milestone payments up to $50 million per product that was developed using Opko intellectual property. RXi will also make royalty payments to OPKO upon commercialization of these products. This will help provide steady inflows as Opko acquires assets from other companies like its recent purchase of two phase 3 products of Cytochroma and a Brazilian pharmaceutical company Silicon Comercio. The phase 3 products may strengthen the company's pipeline while Silicon Comercio may help the company penetrate a new high-growth market. The Full Research Report on Opko Health Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wallstsource.com/r/full_research_report/cb42_OPK]

Amarin Corporation plc (ADR) Research Report

Earlier this year, Amarin filed a Supplemental New Drug Application (sNDA) for Vascepa ANCHOR indication with the FDA and expects action date on the application before 2013. Furthermore, the company has filed more applications to expand its patents, including patent applications related to Vascepa in other countries. Expanding the patent protection for Vascepa helps the product compete in the triglyceride lowering market. The company aims to protect the commercial potential of Vascepa beyond 2030. The Full Research Report on Amarin Corporation plc (ADR) - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wallstsource.com/r/full_research_report/79f9_AMRN]

Progenics Pharmaceuticals, Inc. Research Report

Progenics shares spiked 29 percent after the company crushed Wall Street expectations with a loss of 1 cent per share, as compared to a net loss of 32 cents per diluted share in the 2011 period. This strong result is an effect of higher revenue along with reduced expenses. In the future, Progenics expects to benefit from its out-licensed C. difficile preclinical program of $5 million upfront payment received last January with potential future milestones and royalties. Its acquisition of Molecular Insight Pharmaceuticals is also expected to help the company expand its oncology pipeline with diagnostic and small molecule candidates. Full Research Report on Progenics Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wallstsource.com/r/full_research_report/cd12_PGNX]

Consider Wall Street Source

Tired of hearing about the latest, greatest trade opportunity... only to realize that the ship has long sailed? You need a strong, informative community in your arsenal. Join the group that has been consistently identifying momentous situations as they develop - long before they become the next top news on major financial networks.

Contact: Joe Thomas
Email: [email protected]
Main: +1-310-496-8071 (North America)

SOURCE Wall Street Source